Acceleron Pharma has gained FDA Fast Track designation for ACE-031 which will help to speed its journey through the drug approval process. ACE-031 is a substance that may be able to increase the size and strength of muscle and has the potential to treat a range of muscle diseases. A clinical...
BioMarin has announced disappointing results from the Phase I clinical trial of 'BMN-195' and it has halted development of the compound. BMN-195 is an oral drug with the potential to increase the amount of the protein utrophin in the muscles. Utrophin is thought to be able to substitute for the...